Vidya Parameswaran, MD
Rheumatology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Parameswaran’s office at (408) 357-1425 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A86906 · Current
Licensed to practise in California · since 2004 · expires 2027-09-30 · University of Mumbai, Lokmanya Tilak Municipal Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$234,059
Medicare paid this office $234,059 for 262 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 79 | $122,118 | None |
| Return visit (30+ min) | 207 | $39,622 | $115 |
| Long return visit (40+ min) | 34 | $7,291 | $170 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 172 | $4,009 | $15 |
| New patient visit (60+ min) | 18 | $3,536 | $196 |
See all 7 services
| Injection, denosumab, 1 mg | 79 | $122,118 | None |
| Return visit (30+ min) | 207 | $39,622 | $115 |
| Long return visit (40+ min) | 34 | $7,291 | $170 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 172 | $4,009 | $15 |
| New patient visit (60+ min) | 18 | $3,536 | $196 |
| Short return visit (20+ min) | 34 | $2,767 | $71 |
| Injection of drug or substance under skin or into muscle | 92 | $2,278 | $14 |
Who their Medicare patients are
262 Original Medicare patients in 2024. Average age 76 · Women 77% · Also on Medicaid 7% · Health risk score 1.13. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 71% · Coronary heart disease 27% · Diabetes 20% · Chronic kidney disease 17% · Cancer 17% · Atrial fibrillation 17% · Depression 17% · COPD 13% · Heart failure 9% · Stroke 8% · Dementia 4%.
The office billed $1,044,957, Medicare allowed $298,341 and paid $234,059; for 15,527 services of 27 kinds; $171,592 of it was for drugs given in the office and $62,467 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 262 | 15,527 | 76 | 1.13 | $1,044,957 | $234,059 |
| 2023 | 291 | 16,559 | 75 | 1.21 | $1,296,598 | $296,666 |
| 2022 | 289 | 25,688 | 75 | 1.28 | $1,760,408 | $404,001 |
| 2021 | 313 | 39,800 | 75 | 1.22 | $2,244,287 | $521,868 |
| 2020 | 262 | 27,681 | 75 | 1.26 | $1,752,071 | $393,766 |
| 2019 | 248 | 20,471 | 75 | 1.37 | $1,450,256 | $350,183 |
| 2018 | 234 | 14,978 | 75 | 1.28 | $1,029,439 | $278,084 |
| 2017 | 223 | 20,186 | 75 | 1.27 | $1,038,800 | $256,460 |
| 2016 | 186 | 15,189 | 76 | 1.27 | $613,398 | $152,899 |
| 2015 | 165 | 875 | 74 | 1.67 | $129,033 | $38,244 |
| 2014 | 195 | 1,747 | 72 | 1.43 | $207,475 | $65,025 |
| 2013 | 176 | 1,497 | 72 | 1.51 | $115,226 | $54,092 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Injection, denosumab, 1 mg | 80 | $126,880 | None |
| Return visit (30+ min) | 231 | $55,316 | $114 |
| New patient visit (60+ min) | 52 | $10,763 | $207 |
| Long return visit (40+ min) | 27 | $5,707 | $163 |
| Short return visit (20+ min) | 48 | $4,920 | $82 |
| New patient visit (45+ min) | 23 | $3,372 | $147 |
| Aspiration and/or injection of fluid from large joint | 17 | $2,209 | $76 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $1,993 | $69 |
| Injection of drug or substance under skin or into muscle | 87 | $1,911 | $14 |
| Influenza vaccine split virus, preservative free | 12 | $863 | $72 |
| Administration of influenza virus vaccine | 13 | $480 | $37 |
| Injection, methylprednisolone acetate, 80 mg | 11 | $169 | None |
| Injection, methylprednisolone acetate, 40 mg | 16 | $157 | None |
2022: 13 services
| Injection, denosumab, 1 mg | 68 | $102,064 | None |
| Return visit (30+ min) | 219 | $51,669 | $113 |
| New patient visit (60+ min) | 45 | $8,448 | $188 |
| Long return visit (40+ min) | 32 | $7,113 | $162 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 24 | $5,325 | $73 |
| Short return visit (20+ min) | 43 | $3,697 | $75 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $3,361 | $116 |
| New patient visit (45+ min) | 15 | $2,366 | $158 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,333 | $78 |
| Injection of drug or substance under skin or into muscle | 80 | $1,740 | $14 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,259 | $79 |
| Injection, methylprednisolone acetate, 80 mg | 14 | $205 | None |
| Injection, methylprednisolone acetate, 40 mg | 19 | $177 | None |
2021: 17 services
| Injection, denosumab, 1 mg | 59 | $85,587 | None |
| Injection, tocilizumab, 1 mg | 17 | $81,584 | None |
| Return visit (30+ min) | 181 | $50,027 | $119 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $48,637 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $45,822 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $44,297 | None |
| New patient visit (60+ min) | 63 | $13,910 | $221 |
| Long return visit (40+ min) | 31 | $7,376 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 57 | $7,320 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $5,960 | $115 |
| Short return visit (20+ min) | 60 | $5,829 | $75 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $4,957 | $150 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,327 | $75 |
| Injection of drug or substance under skin or into muscle | 87 | $1,813 | $12 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $1,664 | $69 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,089 | $33 |
| Injection, methylprednisolone acetate, 40 mg | 32 | $294 | None |
2020: 12 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $64,869 | None |
| Injection, denosumab, 1 mg | 44 | $58,028 | None |
| Return visit (30+ min) | 125 | $20,568 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 48 | $7,225 | $106 |
| Short return visit (20+ min) | 80 | $6,907 | $65 |
| New patient visit (60+ min) | 31 | $5,551 | $179 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $5,500 | $76 |
| Telephone medical discussion with physician, 11-20 minutes | 45 | $4,028 | $72 |
| Long return visit (40+ min) | 20 | $2,658 | $116 |
| Aspiration and/or injection of fluid from large joint | 11 | $1,662 | $72 |
| Injection of drug or substance under skin or into muscle | 63 | $1,391 | $13 |
| Injection, methylprednisolone acetate, 40 mg | 18 | $248 | None |
2019: 11 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $63,851 | None |
| Injection, denosumab, 1 mg | 47 | $60,194 | None |
| Return visit (30+ min) | 165 | $37,029 | $94 |
| Short return visit (20+ min) | 87 | $7,955 | $63 |
| Long return visit (40+ min) | 30 | $6,497 | $138 |
| New patient visit (60+ min) | 31 | $6,033 | $195 |
| New patient visit (45+ min) | 23 | $3,137 | $136 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $2,659 | $72 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,200 | $71 |
| Injection of drug or substance under skin or into muscle | 67 | $2,106 | $16 |
| Injection, methylprednisolone acetate, 40 mg | 31 | $389 | None |
2018: 9 services
| Injection, denosumab, 1 mg | 39 | $43,334 | None |
| Return visit (30+ min) | 175 | $38,006 | $93 |
| Short return visit (20+ min) | 85 | $7,700 | $64 |
| New patient visit (45+ min) | 31 | $4,289 | $138 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $3,489 | $74 |
| Long return visit (40+ min) | 13 | $2,177 | $136 |
| Injection of drug or substance under skin or into muscle | 57 | $1,812 | $19 |
| Aspiration and/or injection of fluid from large joint | 12 | $861 | $61 |
| Injection, methylprednisolone acetate, 40 mg | 23 | $302 | None |
2017: 13 services
| Return visit (30+ min) | 195 | $50,750 | $94 |
| Injection, denosumab, 1 mg | 38 | $40,127 | None |
| New patient visit (45+ min) | 60 | $8,385 | $140 |
| Short return visit (20+ min) | 51 | $5,002 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $3,173 | $66 |
| Long return visit (40+ min) | 17 | $2,287 | $114 |
| Injection of drug or substance under skin or into muscle | 51 | $2,028 | $24 |
| Aspiration and/or injection of fluid from large joint | 23 | $1,798 | $54 |
| X-ray of hand, minimum of 3 views | 23 | $1,049 | $23 |
| X-ray of knee, 3 views | 14 | $750 | $27 |
| X-ray of lower and sacral spine, minimum of 4 views | 12 | $448 | $34 |
| Injection, methylprednisolone acetate, 40 mg | 28 | $237 | None |
| X-ray of chest, 2 views, front and side | 11 | $198 | $18 |
2016: 10 services
| Return visit (30+ min) | 133 | $24,478 | $96 |
| Injection, denosumab, 1 mg | 19 | $14,373 | None |
| New patient visit (45+ min) | 93 | $13,910 | $150 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $2,575 | $70 |
| Aspiration and/or injection of fluid from large joint | 22 | $1,892 | $56 |
| Short return visit (20+ min) | 16 | $1,051 | $66 |
| X-ray of hand, minimum of 3 views | 15 | $618 | $22 |
| Injection of drug or substance under skin or into muscle | 20 | $582 | $25 |
| X-ray of lower and sacral spine, minimum of 4 views | 12 | $462 | $38 |
| Injection, methylprednisolone acetate, 40 mg | 26 | $259 | None |
2015: 5 services
| Return visit (30+ min) | 112 | $18,630 | $93 |
| Short return visit (20+ min) | 91 | $8,467 | $65 |
| New patient visit (45+ min) | 21 | $3,226 | $154 |
| Aspiration and/or injection of fluid from large joint | 19 | $1,835 | $68 |
| Injection, methylprednisolone acetate, 40 mg | 28 | $234 | None |
2014: 9 services
| Return visit (30+ min) | 132 | $26,412 | $94 |
| Short return visit (20+ min) | 132 | $15,387 | $60 |
| Aspiration and/or injection of fluid from large joint | 34 | $4,154 | $65 |
| New patient visit (45+ min) | 23 | $3,323 | $144 |
| New patient visit (30+ min) | 16 | $1,589 | $99 |
| Injection of drug or substance under skin or into muscle | 14 | $707 | $24 |
| Administration of influenza virus vaccine | 21 | $654 | $31 |
| Injection, methylprednisolone acetate, 40 mg | 45 | $344 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 19 | $286 | $15 |
2013: 7 services
| Short return visit (20+ min) | 136 | $17,635 | $63 |
| Return visit (30+ min) | 106 | $15,428 | $95 |
| New patient visit (45+ min) | 30 | $4,485 | $149 |
| Aspiration and/or injection of fluid from large joint | 35 | $3,659 | $61 |
| Administration of influenza virus vaccine | 14 | $450 | $32 |
| Injection of drug or substance under skin or into muscle | 13 | $355 | $22 |
| Injection, methylprednisolone acetate, 40 mg | 46 | $304 | None |
Drugs they prescribed that Part D paid
$513,366
Pharmacies billed $513,366 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (61 of 795) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%.
694 generic and fewer than 11 brand-name prescriptions · $513,366 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xeljanz | 20 | $123,981 | $6,199 |
| Tymlos | 12 | $31,974 | $2,665 |
| Hydroxychloroquine Sulfate | 69 | $3,021 | $44 |
| Risedronate | 19 | $2,150 | $113 |
| Celecoxib | 34 | $1,826 | $54 |
See all 18 drugs
| Xeljanz | 20 | $123,981 | $6,199 |
| Tymlos | 12 | $31,974 | $2,665 |
| Hydroxychloroquine Sulfate | 69 | $3,021 | $44 |
| Risedronate | 19 | $2,150 | $113 |
| Celecoxib | 34 | $1,826 | $54 |
| Febuxostat | 18 | $1,725 | $96 |
| Gabapentin | 49 | $1,504 | $31 |
| Methotrexate | 49 | $1,371 | $28 |
| Hydrocodone-Acetaminophen | 29 | $1,339 | $46 |
| Leflunomide | 21 | $1,215 | $58 |
| Prednisone | 71 | $1,036 | $15 |
| Duloxetine | 20 | $794 | $40 |
| Allopurinol | 42 | $688 | $16 |
| Alendronate | 78 | $651 | $8 |
| Pregabalin | 12 | $359 | $30 |
| Folic Acid | 17 | $179 | $11 |
| Tramadol | 17 | $104 | $6 |
| Meloxicam | 15 | $56 | $4 |
Year by year
| 2024 | 795 | 216 | 8% (61) | None | $513,366 |
| 2023 | 1,014 | 240 | 9% (89) | None | $686,719 |
| 2022 | 1,044 | 200 | 11% (112) | None | $688,140 |
| 2021 | 1,036 | 190 | 10% (103) | 14% | $596,913 |
| 2020 | 871 | 162 | 11% (95) | None | $628,032 |
| 2019 | 958 | 196 | 9% (84) | None | $493,068 |
| 2018 | 924 | 163 | 8% (73) | None | $495,964 |
| 2017 | 974 | 135 | 7% (66) | None | $462,692 |
| 2016 | 699 | 142 | 11% (80) | None | $165,766 |
| 2015 | 2,251 | 322 | 10% (218) | None | $256,149 |
| 2014 | 2,858 | 327 | 10% (280) | None | $310,078 |
| 2013 | 2,473 | 295 | 12% (302) | None | $198,705 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Xeljanz | 26 | $155,645 | $5,986 |
| Enbrel Sureclick | 14 | $113,732 | $8,124 |
| Enbrel | 11 | $79,325 | $7,211 |
| Tymlos | 13 | $34,950 | $2,688 |
| Hydroxychloroquine Sulfate | 104 | $6,125 | $59 |
| Methotrexate | 50 | $3,187 | $64 |
| Celecoxib | 43 | $3,098 | $72 |
| Febuxostat | 17 | $2,553 | $150 |
| Leflunomide | 20 | $1,921 | $96 |
| Diclofenac | 29 | $1,687 | $58 |
| Risedronate | 14 | $1,649 | $118 |
| Duloxetine | 37 | $1,368 | $37 |
| Gabapentin | 53 | $1,333 | $25 |
| Hydrocodone-Acetaminophen | 36 | $1,290 | $36 |
| Prednisone | 93 | $1,219 | $13 |
| Alendronate | 91 | $1,108 | $12 |
| Allopurinol | 47 | $1,000 | $21 |
| Oxycodone-Acetaminophen | 15 | $371 | $25 |
| Tramadol | 30 | $306 | $10 |
| Meloxicam | 28 | $245 | $9 |
| Baclofen | 11 | $149 | $14 |
| Naproxen | 19 | $145 | $8 |
| Folic Acid | 20 | $46 | $2 |
2022: 25 drugs
| Xeljanz | 25 | $141,276 | $5,651 |
| Humira(Cf) | 16 | $113,243 | $7,078 |
| Actemra | 25 | $111,951 | $4,478 |
| Enbrel Sureclick | 15 | $103,722 | $6,915 |
| Enbrel | 13 | $83,271 | $6,405 |
| Hydroxychloroquine Sulfate | 86 | $7,750 | $90 |
| Duloxetine | 50 | $4,558 | $91 |
| Celecoxib | 45 | $3,438 | $76 |
| Methotrexate | 64 | $3,149 | $49 |
| Febuxostat | 16 | $2,306 | $144 |
| Prednisone | 126 | $2,204 | $17 |
| Risedronate | 11 | $2,009 | $183 |
| Hydrocodone-Acetaminophen | 41 | $1,650 | $40 |
| Diclofenac | 24 | $1,647 | $69 |
| Leflunomide | 14 | $1,210 | $86 |
| Allopurinol | 52 | $1,136 | $22 |
| Alendronate | 82 | $1,039 | $13 |
| Gabapentin | 44 | $1,038 | $24 |
| Oxycodone-Acetaminophen | 13 | $911 | $70 |
| Pregabalin | 11 | $552 | $50 |
| Tramadol | 43 | $393 | $9 |
| Tizanidine | 11 | $176 | $16 |
| Folic Acid | 22 | $152 | $7 |
| Trazodone | 14 | $126 | $9 |
| Meloxicam | 25 | $122 | $5 |
2021: 21 drugs
| Xeljanz | 22 | $116,429 | $5,292 |
| Enbrel Sureclick | 14 | $88,963 | $6,355 |
| Humira(Cf) | 12 | $76,543 | $6,379 |
| Enbrel | 12 | $71,435 | $5,953 |
| Forteo | 11 | $45,325 | $4,120 |
| Hydroxychloroquine Sulfate | 84 | $7,469 | $89 |
| Celecoxib | 53 | $3,560 | $67 |
| Duloxetine | 63 | $3,157 | $50 |
| Methotrexate | 69 | $2,715 | $39 |
| Diclofenac | 29 | $2,638 | $91 |
| Febuxostat | 14 | $2,525 | $180 |
| Prednisone | 122 | $2,217 | $18 |
| Hydrocodone-Acetaminophen | 37 | $1,429 | $39 |
| Oxycodone-Acetaminophen | 12 | $1,051 | $88 |
| Alendronate | 90 | $898 | $10 |
| Gabapentin | 56 | $898 | $16 |
| Allopurinol | 46 | $840 | $18 |
| Tramadol | 33 | $284 | $9 |
| Folic Acid | 22 | $114 | $5 |
| Meloxicam | 19 | $80 | $4 |
| Trazodone | 12 | $63 | $5 |
2020: 19 drugs
| Forteo | 32 | $135,679 | $4,240 |
| Humira(Cf) | 13 | $77,076 | $5,929 |
| Enbrel | 11 | $61,615 | $5,601 |
| Xeljanz | 12 | $58,348 | $4,862 |
| Hydroxychloroquine Sulfate | 78 | $11,102 | $142 |
| Celecoxib | 40 | $3,954 | $99 |
| Diclofenac | 46 | $3,112 | $68 |
| Methotrexate | 50 | $1,858 | $37 |
| Duloxetine | 31 | $1,688 | $54 |
| Prednisone | 106 | $1,618 | $15 |
| Hydrocodone-Acetaminophen | 35 | $1,350 | $39 |
| Mycophenolate Mofetil | 14 | $1,163 | $83 |
| Alendronate | 65 | $806 | $12 |
| Allopurinol | 34 | $694 | $20 |
| Oxycodone-Acetaminophen | 13 | $570 | $44 |
| Gabapentin | 43 | $553 | $13 |
| Tramadol | 39 | $284 | $7 |
| Tizanidine | 12 | $115 | $10 |
| Meloxicam | 18 | $83 | $5 |
2019: 23 drugs
| Forteo | 22 | $144,452 | $6,566 |
| Humira(Cf) | 12 | $66,890 | $5,574 |
| Humira | 12 | $64,876 | $5,406 |
| Xeljanz | 12 | $54,333 | $4,528 |
| Hydroxychloroquine Sulfate | 102 | $13,799 | $135 |
| Uloric | 17 | $11,930 | $702 |
| Otrexup | 13 | $8,363 | $643 |
| Celecoxib | 37 | $3,577 | $97 |
| Diclofenac | 51 | $3,380 | $66 |
| Leflunomide | 13 | $3,205 | $247 |
| Duloxetine | 61 | $2,622 | $43 |
| Methotrexate | 55 | $1,507 | $27 |
| Prednisone | 119 | $1,456 | $12 |
| Hydrocodone-Acetaminophen | 41 | $1,272 | $31 |
| Oxycodone-Acetaminophen | 11 | $994 | $90 |
| Gabapentin | 52 | $971 | $19 |
| Alendronate | 57 | $737 | $13 |
| Methylprednisolone | 11 | $513 | $47 |
| Allopurinol | 25 | $492 | $20 |
| Tizanidine | 19 | $288 | $15 |
| Cyclobenzaprine | 17 | $238 | $14 |
| Tramadol | 26 | $208 | $8 |
| Meloxicam | 16 | $56 | $4 |
2018: 19 drugs
| Forteo | 23 | $127,900 | $5,561 |
| Humira | 17 | $85,944 | $5,056 |
| Enbrel | 13 | $64,230 | $4,941 |
| Humira | 11 | $52,482 | $4,771 |
| Xeljanz | 12 | $49,812 | $4,151 |
| Hydroxychloroquine Sulfate | 124 | $16,881 | $136 |
| Uloric | 25 | $12,155 | $486 |
| Otrexup | 17 | $11,110 | $654 |
| Methotrexate | 72 | $2,757 | $38 |
| Celecoxib | 29 | $1,783 | $61 |
| Gabapentin | 45 | $1,594 | $35 |
| Duloxetine | 48 | $1,543 | $32 |
| Hydrocodone-Acetaminophen | 44 | $1,456 | $33 |
| Prednisone | 127 | $1,353 | $11 |
| Diclofenac | 27 | $1,289 | $48 |
| Sulfasalazine | 25 | $1,011 | $40 |
| Alendronate | 51 | $616 | $12 |
| Leucovorin | 22 | $605 | $27 |
| Allopurinol | 25 | $380 | $15 |
2017: 20 drugs
| Humira | 23 | $109,301 | $4,752 |
| Humira | 21 | $91,499 | $4,357 |
| Forteo | 29 | $86,646 | $2,988 |
| Xeljanz | 11 | $42,544 | $3,868 |
| Hydroxychloroquine Sulfate | 130 | $21,182 | $163 |
| Otrexup | 26 | $15,642 | $602 |
| Uloric | 18 | $8,366 | $465 |
| Methotrexate | 66 | $3,141 | $48 |
| Risedronate | 15 | $2,448 | $163 |
| Prednisone | 156 | $2,304 | $15 |
| Diclofenac | 37 | $2,238 | $60 |
| Duloxetine | 47 | $1,787 | $38 |
| Celecoxib | 30 | $1,646 | $55 |
| Sulfasalazine | 45 | $1,509 | $34 |
| Hydrocodone-Acetaminophen | 42 | $814 | $19 |
| Alendronate | 59 | $594 | $10 |
| Oxycodone-Acetaminophen | 12 | $580 | $48 |
| Gabapentin | 23 | $530 | $23 |
| Leucovorin | 23 | $348 | $15 |
| Allopurinol | 16 | $150 | $9 |
2016: 15 drugs
| Humira | 16 | $64,025 | $4,002 |
| Hydroxychloroquine Sulfate | 90 | $9,174 | $102 |
| Uloric | 14 | $7,240 | $517 |
| Risedronate | 17 | $4,908 | $289 |
| Duloxetine | 59 | $4,525 | $77 |
| Hydrocodone-Acetaminophen | 54 | $1,930 | $36 |
| Methotrexate | 39 | $1,922 | $49 |
| Prednisone | 119 | $1,372 | $12 |
| Sulfasalazine | 34 | $649 | $19 |
| Diclofenac | 13 | $634 | $49 |
| Gabapentin | 18 | $491 | $27 |
| Alendronate | 44 | $358 | $8 |
| Tizanidine | 16 | $127 | $8 |
| Tramadol | 11 | $59 | $5 |
| Meloxicam | 13 | $43 | $3 |
2015: 29 drugs
| Hydroxychloroquine Sulfate | 220 | $32,410 | $147 |
| Prolia | 32 | $30,168 | $943 |
| Methotrexate | 248 | $19,351 | $78 |
| Uloric | 24 | $11,269 | $470 |
| Duloxetine | 135 | $10,783 | $80 |
| Lyrica | 21 | $10,691 | $509 |
| Risedronate | 23 | $4,108 | $179 |
| Leflunomide | 55 | $4,055 | $74 |
| Hydrocodone-Acetaminophen | 134 | $3,968 | $30 |
| Prednisone | 306 | $3,947 | $13 |
| Gabapentin | 159 | $2,694 | $17 |
| Pilocarpine | 13 | $2,144 | $165 |
| Sulfasalazine | 71 | $2,039 | $29 |
| Voltaren | 13 | $1,759 | $135 |
| Azathioprine | 21 | $1,649 | $79 |
| Alendronate | 173 | $1,606 | $9 |
| Sulfasalazine Dr | 14 | $944 | $67 |
| Allopurinol | 63 | $822 | $13 |
| Cyclobenzaprine | 29 | $733 | $25 |
| Acetaminophen-Codeine | 25 | $618 | $25 |
| Tizanidine | 42 | $606 | $14 |
| Tramadol | 40 | $568 | $14 |
| Meloxicam | 66 | $442 | $7 |
| Omeprazole | 32 | $426 | $13 |
| Sulindac | 18 | $260 | $14 |
| Ranitidine | 23 | $245 | $11 |
| Ibuprofen | 22 | $232 | $11 |
| Baclofen | 20 | $200 | $10 |
| Trazodone | 16 | $92 | $6 |
2014: 38 drugs
| Enbrel | 17 | $47,068 | $2,769 |
| Methotrexate | 321 | $25,210 | $79 |
| Forteo | 14 | $21,191 | $1,514 |
| Celebrex | 37 | $14,882 | $402 |
| Duloxetine | 100 | $14,841 | $148 |
| Lyrica | 35 | $12,724 | $364 |
| Oxycontin | 12 | $10,416 | $868 |
| Hydroxychloroquine Sulfate | 330 | $10,405 | $32 |
| Uloric | 15 | $6,132 | $409 |
| Hydrocodone-Acetaminophen | 160 | $4,490 | $28 |
| Gabapentin | 265 | $4,370 | $16 |
| Prednisone | 368 | $4,366 | $12 |
| Leflunomide | 82 | $3,471 | $42 |
| Actonel | 11 | $3,131 | $285 |
| Pilocarpine | 25 | $2,976 | $119 |
| Colcrys | 18 | $2,383 | $132 |
| Atelvia | 13 | $2,104 | $162 |
| Sulfasalazine | 62 | $1,847 | $30 |
| Alendronate | 159 | $1,551 | $10 |
| Tizanidine | 50 | $1,257 | $25 |
| Azathioprine | 37 | $1,120 | $30 |
| Voltaren | 20 | $1,101 | $55 |
| Sulfasalazine Dr | 26 | $932 | $36 |
| Cyclobenzaprine | 39 | $743 | $19 |
| Sulfazine Ec | 14 | $640 | $46 |
| Acetaminophen-Codeine | 32 | $631 | $20 |
| Tramadol | 49 | $622 | $13 |
| Allopurinol | 84 | $546 | $7 |
| Meloxicam | 80 | $509 | $6 |
| Carisoprodol | 23 | $456 | $20 |
| Ranitidine | 46 | $396 | $9 |
| Sulindac | 26 | $364 | $14 |
| Oxycodone-Acetaminophen | 11 | $347 | $32 |
| Baclofen | 34 | $339 | $10 |
| Sulfazine | 13 | $321 | $25 |
| Omeprazole | 24 | $266 | $11 |
| Ibuprofen | 21 | $206 | $10 |
| Naproxen | 15 | $127 | $8 |
2013: 31 drugs
| Enbrel | 16 | $38,847 | $2,428 |
| Methotrexate | 233 | $15,298 | $66 |
| Oxycontin | 13 | $11,528 | $887 |
| Cymbalta | 36 | $9,588 | $266 |
| Uloric | 26 | $8,841 | $340 |
| Actonel | 36 | $8,503 | $236 |
| Colcrys | 42 | $5,263 | $125 |
| Gabapentin | 209 | $5,051 | $24 |
| Celebrex | 16 | $4,896 | $306 |
| Hydroxychloroquine Sulfate | 295 | $4,720 | $16 |
| Leflunomide | 80 | $3,955 | $49 |
| Hydrocodone-Acetaminophen | 184 | $3,445 | $19 |
| Alendronate | 183 | $2,077 | $11 |
| Prednisone | 268 | $1,829 | $7 |
| Sulfasalazine | 54 | $1,806 | $33 |
| Pilocarpine | 19 | $1,324 | $70 |
| Azathioprine | 27 | $1,134 | $42 |
| Tizanidine | 32 | $702 | $22 |
| Cyclobenzaprine | 78 | $688 | $9 |
| Acetaminophen-Codeine | 39 | $671 | $17 |
| Mycophenolate Mofetil | 11 | $551 | $50 |
| Tramadol | 41 | $512 | $12 |
| Meloxicam | 65 | $497 | $8 |
| Carisoprodol | 28 | $466 | $17 |
| Ranitidine | 50 | $450 | $9 |
| Allopurinol | 79 | $400 | $5 |
| Omeprazole | 26 | $319 | $12 |
| Sulindac | 20 | $307 | $15 |
| Trazodone | 36 | $281 | $8 |
| Folic Acid | 25 | $74 | $3 |
| Ibuprofen | 12 | $71 | $6 |
Money from drug and device companies
$27 in 2025
| 2025 | 1 | 1 | None | $27 |
| 2019 | 1 | 1 | None | $122 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Uplizna | $27 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-10-30 | Uplizna | $27 |
See earlier years (2019)
2019: $122
| GlaxoSmithKline | None | $122 | 1 payment
|
Professional record
- NPI
- 1518078179
- Licence
- CA A86906California A86906: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 50 E Hamilton Ave Ste 200, Campbell, CA, 95008
- NPI first listed
- 2006-08-31
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 700 West Parr Avenue, Suite A,, Los Gatos, CA, 95032